GLP-1 (7-36) amide confers cardiovascular benefits

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1430, 2004-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Continuous GLP-1 (7-36) amide effective in type 2 diabetes

Inpharma, Vol. 1, Iss. 1329, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

GLP-1 7-36 amide: potential in type 2 diabetes

Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1

By Parkes David G Mace Kenneth F Trautmann Michael E

Expert Opinion on Drug Discovery, Vol. 8, Iss. 2, 2013-02 ,pp. : 219-244

Informa Healthcare

Access to resources Recommend Favorite

Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints

Current Pharmaceutical Design, Vol. 24, Iss. 17, 2018-05 ,pp. : 1879-1886

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging GLP-1 receptor agonists

By Lund Asger Knop Filip K Vilsbøll Tina

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 4, 2011-12 ,pp. : 607-618

Informa Healthcare

Access to resources Recommend Favorite